RhumbLine Advisers
STLN icon

RhumbLine Advisers’s Starling Oncology STLN Stock Holding History

RhumbLine Advisers’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$559K Buy
+88,403
New +$528K ﹤0.01% 2658
2026
Q2 		– Sell
-77,845
Closed -$239K – 4256
2026
Q1 		$239K Buy
77,845
+3,260
+4% +$10K ﹤0.01% 3037
2025
Q4 		$266K Sell
74,585
-8,794
-11% -$32.6K ﹤0.01% 3037
2025
Q3 		$291K Sell
83,379
-1,852
-2% -$6.35K ﹤0.01% 3020
2025
Q2 		$175K Buy
+85,231
New +$213K ﹤0.01% 3303
2024
Q3 		– Sell
-2,175
Closed -$1K – 4327
2024
Q2 		$1K Hold
2,175
– – ﹤0.01% 4244
2024
Q1 		$3.44K Hold
2,175
– – ﹤0.01% 4032
2023
Q4 		$4.44K Hold
2,175
– – ﹤0.01% 4004
2023
Q3 		$3.04K Sell
2,175
-10,037
-82% -$10.4K ﹤0.01% 4061
2023
Q2 		$6.72K Sell
12,212
-26,388
-68% -$14K ﹤0.01% 4032
2023
Q1 		$26K Buy
38,600
+1,818
+5% +$2.32K ﹤0.01% 2930
2022
Q4 		$61K Buy
36,782
+1,154
+3% +$3.24K ﹤0.01% 2945
2022
Q3 		$165K Buy
35,628
+13,141
+58% +$77.3K ﹤0.01% 2932
2022
Q2 		$114K Buy
+22,487
New +$164K ﹤0.01% 3023

Other funds holding STLN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Mount Lucas Management
Mount Lucas Management Newtown, Pennsylvania $333M AUM 24.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Kingswood Wealth Advisors
Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return

RhumbLine Advisers's STLN Position: Q3 2026 in Review

RhumbLine Advisers opened a new position in Starling Oncology (STLN) in Q3 2026: 88,403 shares worth $559K. The stake represents ﹤0.01% of the portfolio and ranks #2658 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in STLN as recently as Q1 2026.

RhumbLine Advisers first reported a position in STLN in Q2 2022 and has held it in 14 quarters since. 55 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • RhumbLine Advisers held 88,403 shares of Starling Oncology worth $559K as of Q3 2026.
  • Starling Oncology was a new RhumbLine Advisers position in Q3 2026.
  • Starling Oncology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2658 holding.
  • RhumbLine Advisers first reported a position in Starling Oncology in Q2 2022 and has held it in 14 quarters since.
  • 55 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.